.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Medtronic
Fish and Richardson
Deloitte
McKesson
Boehringer Ingelheim
Julphar
Accenture
Farmers Insurance
McKinsey

Generated: July 25, 2017

DrugPatentWatch Database Preview

Levoleucovorin calcium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for levoleucovorin calcium and what is the scope of levoleucovorin calcium patent protection?

Levoleucovorin calcium
is the generic ingredient in two branded drugs marketed by Actavis Llc, Spectrum Pharms, Amneal Pharms Co, West-ward Pharms Int, Sandoz Inc, and Mylan Teoranta, and is included in seven NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Levoleucovorin calcium has twenty-one patent family members in nine countries.

There is one drug master file entry for levoleucovorin calcium. Six suppliers are listed for this compound.

Summary for Generic Name: levoleucovorin calcium

Tradenames:2
Patents:2
Applicants:6
NDAs:7
Drug Master File Entries: see list1
Suppliers / Packagers: see list6
Bulk Api Vendors: see list25
Clinical Trials: see list1,764
Patent Applications: see list3,666
Drug Prices:see low prices
DailyMed Link:levoleucovorin calcium at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Llc
LEVOLEUCOVORIN CALCIUM
levoleucovorin calcium
POWDER;IV (INFUSION)208723-001Sep 29, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Amneal Pharms Co
LEVOLEUCOVORIN CALCIUM
levoleucovorin calcium
POWDER;IV (INFUSION)207547-001Feb 13, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Spectrum Pharms
FUSILEV
levoleucovorin calcium
SOLUTION;IV (INFUSION)020140-002Apr 29, 2011DISCNYesNo► Subscribe► Subscribe► Subscribe
Actavis Llc
LEVOLEUCOVORIN CALCIUM
levoleucovorin calcium
POWDER;IV (INFUSION)206516-001Feb 13, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
LEVOLEUCOVORIN CALCIUM
levoleucovorin calcium
SOLUTION;IV (INFUSION)203563-002Mar 9, 2015APRXNoYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: levoleucovorin calcium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,959,472 Process for preparing substantially pure diastereoisomers of tetrahydrofolic derivatives► Subscribe
6,849,628 Optically active compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: levoleucovorin calcium

Country Document Number Estimated Expiration
European Patent Office1275393► Subscribe
Austria295173► Subscribe
Austria231150► Subscribe
United Kingdom8621268► Subscribe
Japan2844532► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Novartis
Moodys
Chinese Patent Office
McKinsey
Cerilliant
Cipla
Harvard Business School
Daiichi Sankyo
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot